ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026)

ImmunityBio (IBRX) has 10 years of Other Operating Expenses data on file, last reported at $67.6 million in Q1 2026.

• Quarterly Other Operating Expenses rose 39.53% year-over-year to $67.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $353.0 million (down 18.14% YoY) and the FY2025 annual result came in at $366.4 million, up 3.79% from the prior year.
• Other Operating Expenses eased to $67.6 million in Q1 2026 per IBRX's latest filing, from $101.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $360.7 million in Q4 2023 and bottomed at $681000.0 in Q4 2022.
• The 5-year median for Other Operating Expenses is $93.4 million (2024), against an average of $112.6 million.
• The widest annual swing landed in 2023, when Other Operating Expenses surged 52862.11%; it then plunged 48.82% in 2025.
• Tracing IBRX's Other Operating Expenses over 5 years: stood at $681000.0 in 2022, then surged by 52862.11% to $360.7 million in 2023, then sank by 45.03% to $198.3 million in 2024, then tumbled by 48.82% to $101.5 million in 2025, then slumped by 33.35% to $67.6 million in 2026.
• Per Business Quant, the three latest IBRX Other Operating Expenses figures stand at $67.6 million (Q1 2026), $101.5 million (Q4 2025), and $87.1 million (Q3 2025).

Peer Comparison